Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity Disorder (Q22241421)

Dimensions Publication ID

Dimensions

1038072191

7 February 2023

Ming-Horng Tsai

series ordinal

2

author given names

Ming-Horng

author last names

Tsai

1 reference

Dimensions Publication ID

Dimensions

1038072191

https://scigraph.springernature.com/pub.10.2165/11589380-000000000-00000

7 February 2023

language of work or name

English

0 references

publication date

July 2011

0 references

published in

CNS Drugs

0 references

volume

25

0 references

issue

7

0 references

page(s)

539-554

0 references

exact match

0 references

cites work

National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Treatment of attention-deficit/hyperactivity disorder: overview of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

National trends in the treatment of attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Prevalence of methylphenidate use among Israeli children: 1998-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Diagnosis and treatment of adult attention-deficit/hyperactivity disorder at US ambulatory care visits from 1996 to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Trends in the prescribing of psychotropic medications to preschoolers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Attention-deficit-hyperactivity disorder: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

ASHP therapeutic position statement on the appropriate use of medications in the treatment of attention-deficit/hyperactivity disorder in pediatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Stimulant treatment over five years: adherence, effectiveness, and adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

3-Year Follow-up of the NIMH MTA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Long-term effects of extended-release mixed amphetamine salts treatment of attention- deficit/hyperactivity disorder on growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Stimulant treatment over 5 years: effects on growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Stimulants and sudden death: what is a physician to do?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Short-term cardiovascular effects of methylphenidate and adderall

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

ADHD drugs and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder

21 January 2018

2 references

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

21 January 2018

12 December 2020

Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Attention-deficit/hyperactivity disorder and early-onset substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Quality of life and attention-deficit/hyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Childhood and adolescent hyperactivity-inattention symptoms and academic achievement 8 years later: the GAZEL Youth study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Positive association between attention-deficit/ hyperactivity disorder medication use and academic achievement during elementary school.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Stimulant treatment in children with attention-deficit/hyperactivity disorder moderates adolescent academic outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Issues in the management of patients with complex attention-deficit hyperactivity disorder symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Long-Term Effects of Methylphenidate Transdermal Delivery System Treatment of ADHD on Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Does Prolonged Therapy With a Long-Acting Stimulant Suppress Growth in Children With ADHD?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Effects of Stimulant Medication on Growth Rates Across 3 Years in the MTA Follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589380-000000000-00000

Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder

21 January 2018

1 reference

12 December 2020

Comparing the efficacy of medications for ADHD using meta-analysis

1 reference

12 December 2020

Clinical suggestions for management of stimulant treatment in adolescents

1 reference

12 December 2020

Attention deficit hyperactivity disorder symptoms predict nicotine dependence and progression to regular smoking from adolescence to young adulthood

1 reference

12 December 2020

Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine.

1 reference

12 December 2020

Tourette disorder and ADHD.

1 reference

12 December 2020

Can we prevent smoking in children with ADHD: a review of the literature.

1 reference

12 December 2020

Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.

1 reference

12 December 2020

Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Trends in the prevalence of chronic medication use in children: 2002-2005

1 reference

12 December 2020

A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD

1 reference

12 December 2020

Which aspects of ADHD are associated with tobacco use in early adolescence?

1 reference

12 December 2020

Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD.

1 reference

12 December 2020

Effects of long-term psychostimulant medication on growth of children with ADHD

1 reference

12 December 2020

Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial

1 reference

12 December 2020

A one year trial of methylphenidate in the treatment of ADHD

1 reference

12 December 2020

OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study.

1 reference

12 December 2020

Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes?

1 reference

12 December 2020

Growth deficits in children with attention deficit hyperactivity disorder

1 reference

12 December 2020

A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year

1 reference

12 December 2020

Methylphenidate and substance abuse: a review of pharmacology, animal, and clinical studies

1 reference

12 December 2020

Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis.

1 reference

12 December 2020

Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Effect of stimulants on height and weight: a review of the literature

1 reference

12 December 2020